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A B S T R A C T   
Objectives: To reduce all-cause maternal and perinatal mortality and major morbidity through Lady Health 
Worker (LHW)-facilitated community engagement and early diagnosis, stabilization and referral of women with 
preeclampsia, an important contributor to adverse maternal and perinatal outcomes given delays in early de-
tection and initial management. 
Study design: In the Pakistan Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomized 
controlled trial (NCT01911494), LHWs engaged the community, recruited pregnant women from 20 union 
councils (clusters), undertook mobile health-guided clinical assessment for preeclampsia, and referral to facil-
ities after stabilization. 
Main outcome measures: The primary outcome was a composite of maternal, fetal and newborn mortality and 
major morbidity. 
Findings: We recruited 39,446 women in intervention (N = 20,264) and control clusters (N = 19,182) with 
minimal loss to follow-up (3∙7% vs. 4∙5%, respectively). The primary outcome did not differ between inter-
vention (26·6%) and control (21·9%) clusters (adjusted odds ratio, aOR, 1∙20 [95% confidence interval 0∙84- 
1∙72]; p = 0∙31). There was reduction in stillbirths (0·89 [0·81-0·99]; p = 0·03), but no impact on maternal death 
(1·08 [0·69, 1·71]; p = 0·74) or morbidity (1·12 [0·57, 2·16]; p = 0·77); early (0·95 [0·82-1·09]; p = 0·46) or late 
neonatal deaths (1·23 [0·97-1·55]; p = 0·09); or neonatal morbidity (1·22 [0·77, 1·96]; p = 0·40). Improvements 
in outcome rates were observed with 4–7 (p = 0·015) and ≥8 (p  <  0·001) (vs. 0) CLIP contacts. 
Interpretation: The CLIP intervention was well accepted by the community and implemented by LHWs. Lack of 
effects on adverse outcomes could relate to quality care for mothers with pre-eclampsia in health facilities. 
Future strategies for community outreach must also be accompanied by health facility strengthening. 
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1. Introduction 
The Global Burden of Disease estimates that Pakistan, the world’s 
sixth most populous country, endures the world’s third highest burden 
of maternal mortality (348·6/100,000 live births [95% uncertainty in-
tervals (UI) 247·2-447·0]), stillbirth (27·6/1000 births [95% UI 23·1- 
32·8]), and under-five child mortality (58·0/1000 live births [95% UI 
50–69]) [1,2]. In addition, Pakistan is recognised to have the highest 
neonatal mortality rate globally [3]. 
Such adversity is associated with sociocultural factors and health 
system-related barriers to accessing and receiving the best evidence- 
based care [4–7]. Among the barriers, delays in recognition of illness 
and seeking care contributed to 36% of maternal deaths in 2006 [7]. 
Formative research in Sindh Province reveals the importance of hus-
bands and mothers-in-law as decision makers in health care utilization  
[4]. Poor availability of transport, financial constraints, and limited 
mobility of women are important additional barriers to seeking care. 
In response, the government of Pakistan has invested in health 
strategies and outreach services targeting poor and marginalised po-
pulations. The public health sector is comprised of primary-, sec-
ondary-, and tertiary-level health facilities, while the private health 
sector includes informal care providers (i.e., traditional birth attendants 
and spiritual healers) and formal medical clinics and/or hospitals. The 
mainstay of rural primary care is a cadre of community health workers 
(Lady Health Workers [8], LHWs). LHWs (currently almost 100,000) 
receive formal training for 15 months including didactic course work 
(3 months) and a 12-month practicum. They provide mainly maternal, 
newborn and child health (MNCH) preventative services, health pro-
motion and referrals, as needed, to 100–150 households, covering 70% 
of the rural populations in major provinces. LHWs receive monthly 
Fig. 1. Map of study area and enrollment by cluster.  
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refreshers and replenishment of supplies in the primary care facilities of 
respective districts. On average, as noted in external evaluation [8], 
LHWs work on average five hours daily, visit an average 27 households 
per week and provide advice to an average 22 clients, usually women 
per week. Their current stipend is PKR 27,000 per month (US$ 173). 
Pregnancy hypertension is associated with maternal and perinatal 
morbidity and mortality risks worldwide, particularly in less-developed 
countries like Pakistan [9]. There is a general lack of understanding by 
women of the implications of having, and by health care providers of 
best evidence-based care of, pregnancy hypertension [4]. The detection 
and management of pregnancy hypertension is an important compo-
nent of antenatal care (ANC) attendance [10]; its implementation re-
flects the quality of care in pregnancy. In resource-constrained en-
vironments such as Pakistan, standards against which health care 
delivery is benchmarked are often basic, such as whether BP or pro-
teinuria were tested at least once in pregnancy, when each of these 
practices is to be delivered serially over the course of pregnancy [11]. 
Also, despite national policy, supplies of essential commodities (e.g., 
magnesium sulphate) are inadequate and few birthing facilities have 
established protocols for eclampsia management. 
A number of innovations have been tested and introduced through 
the LHW programme, especially targeting perinatal and newborn care 
and childhood illnesses and immunisations [12–15]. However, they 
neither carry blood pressure (BP) measurement devices nor receive 
training about pregnancy hypertension management. 
We hypothesised that training LHWs in community engagement (to 
raise awareness of, and education about, general pregnancy risks and, 
specifically, pregnancy hypertension) as well as community-based as-
sessment, triage, and initial treatment of pre-eclampsia would improve 
maternal and perinatal outcomes. The aim of the Community-Level 
Interventions for Pre-eclampsia (CLIP) cluster randomised controlled 
trial (cRCT) in Sindh Province, Pakistan was to reduce maternal and 
perinatal mortality and major morbidity by 20% or more in interven-
tion (vs. control) clusters, through a community-level intervention to 
address triage, (initial) treatment, and transport (to facility) of women 
with pregnancy hypertension. 
2. Methods 
The full protocol has been published (https://clinicaltrials.gov/ct2/ 
show/NCT01911494; Supplementary Appendix 1), and approved by 
the ethics review committees of the Aga Khan University (AKU, 2590- 
Obs-ERC-13); University of British Columbia (UBC, H12-03497). 
2.1. Study setting and trial design 
The CLIP Pakistan trial was one of three independently powered 
cRCTs (others in India and Mozambique; all NCT01911494), and was 
conducted in Matiari and Hyderabad districts, Sindh Province, ap-
proximately 150 km north of Karachi (Fig. 1). Matiari is rural and lo-
cated 25 km north of Hyderabad (population: ≈600,000). Hyderabad is 
semi-urban (population: ≈1,883,000; second most-populous district in 
Sindh). The consistent population density is 4·7 people/hectare. The 
vast majority of residents are Muslim, agriculturalists, and speak either 
Sindhi and/or Urdu. Literacy rates are 40% (Matiari) to 50% (Hyder-
abad). While women in the study region know about high blood pres-
sure (BP) and seizures in pregnancy, they do not associate the two and 
they attribute hypertension to stress or weakness [4]. They have no 
Sindhi term for the most dangerous form of pregnancy hypertension, 
pre-eclampsia. 
The pilot phase (from 7 February 2014 to 18 January 2015), aimed 
at assessing acceptability of the intervention, and transitioned to the 
definitive phase (from 19 January 2015 to 31 December 2016) based on 
≥50% acceptance by women of health facility referral when indicated 
by the CLIP intervention (using data to 31 October 2014); no additional 
outcomes were assessed at the end of the pilot phase. Recruitment of 
new women ended on 30 September 2016, to allow time for recruited 
women to deliver by trial end on 31 December 2016. 
2.2. Participants 
Married pregnant women aged between 15 and 49 years were 
identified by the trial surveillance teams and written informed consent 
obtained for participation and quarterly data collection in surveillance 
visits. 
2.3. Intervention 
In the intervention clusters, the CLIP intervention package consisted 
of an annual group mobilisation meeting with about ten community 
leaders in each village, and LHW-led visits with eligible women in their 
homes, with a focus on the detection and management of pregnancy 
hypertension (Fig. S1). At the first home visit and again at around seven 
to eight months of pregnancy, LHWs engaged each participant herself, 
in her home, along with her immediate community (e.g., mother, mo-
ther-in-law, and female family or friends as she wished and were 
available). Activities were supported by culturally-appropriate picto-
grams developed with the LHW programme and describing maternal 
and perinatal risks associated with pregnancy hypertension, as well as 
awareness-raising and education about birth preparedness and com-
plication readiness (e.g., prior permissions for care-seeking, transport 
plans, and funding care of obstetric emergencies). 
In intervention areas, the LHWs were encouraged to provide dom-
iciliary visits every four-weeks (< 28 weeks), fortnightly 
(28–35 weeks), weekly (≥36 weeks until birth), within 24 h of birth, 
and on postpartum days 3, 7, and 14. Given the nature of tasks per-
formed by LHWs, these visits were not mandated by LHW supervisors. 
Tasks were guided by the tablet-based PIERS On the Move (POM) 
mobile health (mHealth) application (app) [16], that included the 
miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) time of disease 
risk stratification [17] with pictograms as visual prompts. Altogether 
223 LHWs (and associated 13 Lady Health Supervisors) were trained to 
provide the CLIP intervention. The three-day didactic and participatory 
training consisted of BP measurement and use of the CLIP POM tool, 
with feedback and reinforcement intervention provided at regular 
monthly meetings. 
In brief, the POM directed LHWs to first observe women to rule out 
emergency conditions (illustrated by pictograms) that would warrant 
immediate referral to a facility. In the absence of emergency conditions, 
LHWs were directed to measure BP twice, using standardised methods 
and a semi-automated digital device validated for use in pregnancy 
(Microlife BP 3AS1-2) [18]; a third measurement was required if either 
the systolic or diastolic BP differed by more than 10 mmHg between the 
first two readings. From January 2015 to December 2016, LHWs also 
used a pulse oximeter to perform peripheral capillary oxygen saturation 
(SpO2) at the first and any subsequently hypertensive visit [19]. 
The CLIP POM tool stratified women into one of three care path-
ways: usual ante-/postnatal care, non-urgent referral to a comprehen-
sive emergency obstetric care (CEmOC) or higher facility within 24 h, 
or urgent referral to a CEmOC or higher facility within four hours. In 
addition, women could be recommended to receive oral anti-
hypertensive therapy (for severe hypertension) or intramuscular mag-
nesium sulphate (for evidence of pre-eclampsia) (Fig. S1). In control 
clusters, women received routine ANC provided at PHCs by nurses and 
doctors and additional routine LHW domiciliary visits. 
During 2015, health care providers from all secondary and tertiary, 
public and private facilities in the districts received three professional 
development sessions immediately prior to launching the trial and 
twice during the first year, focussed on evidence-based detection and 
management of pregnancy hypertension. 
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2.4. Baseline survey and surveillance 
In intervention and control clusters, 20 LHW programme-in-
dependent surveillance teams (140 individuals) were trained to un-
dertake quarterly cross-sectional visits. Each team consisted of one male 
team leader (chaperone) and six female data collectors who visited all 
households and screened for married, pregnant women aged 
15–49 years. Following informed consent, baseline individual- and 
household-level data were collected (Table 1). At each visit registered 
women were asked about antenatal care-seeking and birth prepared-
ness, and postpartum, about adverse maternal (< 42 days postpartum), 
fetal, or neonatal events (< 28 days). When maternal or perinatal 
deaths were identified, an independent, experienced team was notified 
to perform verbal and social autopsies. 
Data collection tools were developed iteratively with local in-
vestigators, derived from existing validated questionnaires where 
possible (e.g., WHO 2012 Verbal and Social Autopsy,[20] and trans-
lated to Sindhi (local language). Data were collected initially on paper 
forms (pilot phase) and then electronically using tablets (definitive 
phase). Data management protocols ensured data security by encryp-
tion, data tracking through user identification numbers and audit trails, 
and effective data synchronisation between within-cluster devices and 
the REDCap server (Vanderbilt University, USA) at UBC. 
2.5. Outcomes (Panel 1) 
The primary outcome was a composite of all-cause maternal, fetal, 
and newborn mortality and major morbidity. Pregnancies with multiple 
elements of the primary outcome were only counted once and no 
weighting was used. In addition to stillbirths, maternal and newborn 
deaths were estimated until 42 and 28 days after birth respectively. 
Maternal morbidity consisted of serious end-organ complications that 
included, but were not limited to, those related to pregnancy hy-
pertension. Neonatal morbidity reflected problems related to early de-
livery or delivery of a baby in poor health. All deaths, as well as sur-
vived morbidities, were reviewed on a quarterly basis by an 
independent panel of physicians, masked to the cluster of origin, and 
excluding individuals who cared for the woman or baby under review. 
The major secondary outcomes were birth preparedness and com-
plication readiness, delivery in a facility able to provide emergency 
obstetric care, and proportion of facility births. Other outcomes in-
cluded pre-eclampsia knowledge and awareness before birth, gesta-
tional age at birth, and mode of delivery. 
2.6. Sample size and randomisation 
Assuming an annual birth rate of 14/1000/year in each cluster, a 
baseline incidence of maternal and perinatal mortality and morbidity of 
9·6% in control clusters, 10% loss to follow-up, an intra-cluster co-ef-
ficient (ICC) of 0·002, and a 20% reduction in all cause maternal, fetal, 
and newborn morbidity and mortality, an alpha of 0·05, and 80% 
power, we calculated that we would require 20 clusters over two years. 
The data upon which the estimates were based on the published or 
available ranges and were provided by the site investigators based on 
recent surveillance data. A predetermined review of these sample size 
assumptions using data from the CLIP feasibility study, pilot and defi-
nitive trials was conducted independently by the statistical team (JB, 
TL, HW, JS) at study midpoint. 
The unit of randomisation (cluster) was a Union Council (average 
population 32,000), and all associated villages and primary health 
centres (PHCs). The local team chose potential clusters based on com-
parability of health care infrastructure, surveillance team accessibility, 
and the absence of conflicting concurrent research activity. Restricted, 
stratified randomisation was undertaken according to population size. 
There were 3424 possible allocations of clusters to intervention or 
control, from which one was randomly selected. Two intervention and 
control clusters were chosen for the pilot phase based on their im-
plementation readiness. 
2.7. Statistical analysis (full plan, Appendix 2) 
All pregnancies, except those of women who withdrew, were in-
cluded in our primary, intention-to-treat analyses. The unit of analysis 
was pregnancy, classified as ‘followed-up’ (complete postpartum trial 
surveillance), ‘lost-to-follow-up’ (estimated date of delivery [EDD] 
at ≥ 3 weeks before trial end but without follow-up data), and ‘still-on 
follow-up’ (EDD  <  3 weeks before trial end). 
To mitigate potential bias due to differential loss-to and incomplete 
follow-up, the primary outcome of women who were lost-to, or still-on, 
follow-up was imputed ten times via multiple imputation by chain 
equations and Rubin’s rules [21]. Imputation models were based on all 
primary analysis adjustment factors (see below) and interactions 
Table 1 
Baseline characteristics.      
Intervention  
(n = 20,235 
pregnancies) 
Control  
(n = 19,182 
pregnancies)  
Clusters 10 10 
Population density (n/ha) * 4·1 5·3 
Estimated annual birth rate/cluster 
(n/1000) 
22 22 
LHWs/cluster 21 [17,30] 21 [13, 21.8] 
Neonatal mortality ratio/1000 live 
births (in previous 12 months 
at baseline) * 
27 [25·1, 36·8] 28·3 [20·7, 34·1] 
Households 16,373 15,569 
Enrolled pregnancies 20,235 19,182 
Nature of respondent was woman 
herself 
19,737 (97·5%) 18,612 (97·0%) 
Maternal age (year) * 28 [25,30] 28 [25,30] 
Married 20,186 (99·8%) 19,109 (99·6%) 
Religion   
Muslim 16,806 (83·1%) 15,637 (81·5%) 
Hindu 3374 (16·7%) 3472 (18·1%) 
Other 18 (0·1%) 5 (0·02%) 
Women with ≥ 5 years of schooling 
* 
3971 (19·6%) 3277 (17·1%) 
Husbands with ≥ 5 years of 
schooling † 
9532 (47·2%) 8247 (43·2%) 
Obstetric history   
Parous * 15,540 (77·0%) 14,981 (78·4%) 
Parity 2 [1,4] (missing 
0·3%) 
2 [1,4] (missing 
0·4%) 
Amongst previously pregnant 
women   








Delivery location in previous 
pregnancy †   
Home 5051 (31·1%) 5301 (34·1%) 
CEmOC (hospitals) 7813 (48·0%) 7522 (48·4%) 
Non-CEmOC facility 3342 (20·6%) 2645 (17·0%) 
ANC care sought ** 13,375 (72.5%) 14,153 (81.6%) 
Current pregnancy   
Gestational age at enrolment 
(week) 
19·8 [14·1, 26·8] 20·6 [14·9, 27·4] 
Multiple pregnancy 171 (0·8%) 182 (0·9%) 
Data presented as median [interquartile range] or number (%). * Variables used 
as adjustment factors in analyses, chosen a priori. † Variable used as adjustment 
factor in analyses, chosen following review of baseline data prior to knowledge 
of outcomes. ‡ Not asked in pilot phase. ** ANC care sought includes only visits 
with a mandated blood pressure measurement, excluding LHW CLIP contacts 
and all other LHW contacts. 
LHW = Lady Health Worker. CEmOC = Comprehensive emergency obstetric 
care.  
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between trial arm and enrolment date (accounting for possible lag in 
intervention effects). In each imputed data set, the adjusted odds ratio 
(OR) for the intervention effect was estimated using a multi-level lo-
gistic regression including a random intercept term for each cluster. To 
improve precision, models were adjusted for variables at individual 
(i.e., age, parity, maternal primary education, previous delivery loca-
tions, and husband’s primary education) and cluster-level (i.e., baseline 
neonatal mortality rate, LHW density, and population density). Sensi-
tivity analysis including only complete cases was conducted with the 
same adjustment variables. 
Further, analogous multi-level logistic regression models were fit to 
assess the sensitivity of the primary result to various other factors, in-
cluding adjustment, missing data for a component of the primary out-
come (when others were documented), gestational age at birth, and 
postpartum follow-up to  <  42 days, as well as cluster-level aggregate 
analysis. Where sensitivity analyses included imputation, results were 
pooled (Rubin’s rules) [21]. In an additional planned secondary ana-
lysis, we explored within the intervention arm, whether there was a 
relationship between our primary outcome and the intensity of CLIP 
contacts, categorised as 0, 1–3, 4–7, or ≥8, to reflect prior and current 
WHO recommendations for the frequency of antenatal contacts [22]; to 
account for factors related to the number of POM-guided visit and 
confounders, the analysis was adjusted for maternal age, basic educa-
tion, parity, enrolment timing in the trial, and distance from the 
household to facility. 
All analyses were repeated for each component of the primary 
outcome, albeit without imputation. Secondary and other outcomes 
were compared by baseline factor-adjusted multi-level models, as 
above. Statistical significance (two-sided) was set at p  <  0·05 for the 
primary and p  <  0·01 for other analyses, without adjustment for the 
interim analysis. R statistical software was used throughout. 
An interim analysis was undertaken once complete data were re-
ceived for women making up half of the planned sample size and re-
viewed by the data safety and monitoring board (DSMB). The stopping 
rule for both benefit and harm required an observed difference between 
groups associated with an alpha  <  0·001 (power 80%). The DSMB 
reviewed all reported adverse events for participant safety. 
3. Results 
Between 7 February 2014 and 30 September 2016, 35,974 women 
(39,417 pregnancies) were recruited in 10 intervention (20,238 preg-
nancies) and 10 control (19,186 pregnancies) clusters. Of these preg-
nancies, 4357 (2231 in the intervention vs. 2126 in the control arm) 
were from the pilot phase. After accounting for 7 withdrawals, 20,235 
and 19,182 pregnancies in intervention and control clusters, respec-
tively, were included in the analysis (Fig. 2). 
Pregnancies in intervention and control clusters were broadly si-
milar at baseline, with most information coming directly from the 
participating woman herself (Table 1, Table S2). Women were generally 
in their late 20s; virtually all were married (some were either widowed 
or divorced between conception and recruitment) and self-identified as 
Muslim. Most had no basic education although almost half of their 
husbands did. Women were generally parous and when so, reported 
high rates of prior stillbirth (≈15%) and neonatal death (≈15%) 
(Table S2). Few women (< 1%) had multiple pregnancies. Generally, 
women were enrolled at ≈20 weeks’ gestation (Table 1). 
LHW coverage varied widely between clusters (range: 9% (Odero 
Lal Station) to 98% (Bhanoth)). There were 1368 community engage-
ment sessions/cluster (total of 793 men’s group sessions (7784 parti-
cipants) and 16,691 LHW-led sessions in pregnant women’s homes). 
The visit number compliance target of 12 visits during pregnancy 
and the post-natal period was met in 5723 (28.3%) pregnancies. Of the 
total 58,174 visits, 10,529 women (11,399 pregnancies [56·6%]) re-
ceived ≥ 1 LHW-provided POM visit, for a median of 5 [IQR 3, 7] visits 
per pregnancy when received. Most visits were antenatal (40,264 
[69·2%]). Compliance with BP measurement at all visits, and protei-
nuria testing during first and all hypertensive visits, was almost uniform 
(99·9% and 98·4%, respectively). 
POM-guided advice for referrals, whether non-urgent (2·5% of 
pregnancies) or urgent (1·4% of pregnancies), were accepted 77% of the 
time. Non-urgent referral (2·5%) was for non-severe hypertension. 
Urgent referral (1·4%) was most commonly for severe hypertension 
(153/218, 70·2%) or absent fetal movements in the preceding 24 h (24/ 
218, 11·0%), and accepted 84·9% of the time. Intramuscular magne-
sium sulphate (for pre-eclampsia) was recommended in 166 (0·3%) of 
POM visits and accepted in 96 visits (58·3% of the time). Oral me-
thyldopa (for severe hypertension) was recommended in 153 (0·3%) 
visits and accepted in 148 visits (96·8% of the time). Details of the in-
dications for referral according to the CLIP triggers, and LHW actions, 
can be found in Table S3 and Figs. S1 and S2. 
There was no significant difference in ≥4 ANC visits for women in 
intervention (44·6%) vs. control (31·7%) clusters (aOR 1·84 95% CI 
[0·89-3·83]; p = 0·032). 
The composite primary outcome (one or more element) occurred in 
more than 20% of pregnancies, related primarily to major maternal 
morbidity and fetal/newborn death (≈10% each) (Table 2). The pri-
mary outcome did not differ between intervention and control clusters 
overall (aOR 1·20 [0·84–1·72]; p = 0·31) (Table 2), or by cluster (Table 
S4). Major maternal morbidity was 37 times more common than was 
maternal death (2·7/1000 identified pregnancies). Stillbirths 
(≥20 weeks) and neonatal death each complicated ≈5% of pregnan-
cies. Overall, there were no significant differences between the groups 
for the most common major maternal morbidities (sepsis (6.8%), fol-
lowed by antepartum haemorrhage (2·9%) and blood transfusion 
(1·0%)). The most common major neonatal morbidity was feeding dif-
ficulty (3·1%), followed by lethargy (3·0%) and hypothermia (1·8%). 
There was no difference in intervention (vs. control) clusters for 
birth preparedness (42·4% vs. 29·1%, respectively; aOR 2·41 [0·67- 
8·67]; p = 0·08) or pre-eclampsia knowledge and awareness (16·8% vs. 
14·7%, respectively; aOR 1·11 [0·33-3·69]; p = 0·83). 
Within intervention clusters, women who received both 4–7 and at 
least eight POM guided contacts experienced fewer adverse outcomes 
compared with women who received no contacts (28·8% (4–7) and 
23·2% (≥8) vs 30·5% (0), respectively (aOR 0·89 [95% CI 0·81-0·98]; 
p = 0·015 and 0·66 [95% CI 0·58-0·76]; p  <  0·001, respectively) 
(Table 3; Fig. S3). Women with 1–3 POM-guided contacts did not have 
apparent benefit compared with those without POM contacts (Table 3;  
Fig. S3). Rates of stillbirth were higher in the 1–3 contact group (7·4% 
vs 5·7%; aOR 1·50 [95% CI 1·24–1·82]; p  <  0·001), with a trend to 
more neonatal deaths (p = 0·029), compared with those receiving no 
contacts (Table 3; Fig. S3). 
A single adverse event was reported due to administration of the 
intervention to a non-pregnant woman who had not been enrolled 
(Table 4). The event was identified promptly, and trial activities paused 
during steering committee review of events. The DSMB concluded that 
no harm resulted from these actions. 
4. Discussion 
In the primary, pre-defined analysis, the CLIP Pakistan Trial inter-
vention did not have a significant impact on either the composite 
outcome of maternal, fetal, newborn mortality and severe morbidity, or 
individual components thereof. This was an effectiveness trial with 
functional public sector LHWs, who despite busy workloads were able 
to undertake the recommended number of home visits in nearly half the 
cases. The intervention was reasonably well received by families though 
the overall reported morbidities detected by POM were low. 
The finding of a positive effect of contact intensity of at least four 
contacts, and more so with at least eight contacts, provides data to 
support both the previous and current WHO recommendations.[22] 
While the current WHO recommendations are based on improved 
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perinatal outcomes, our findings (vs. 0 contacts) imply both maternal 
and perinatal outcomes improved (Table 3 and Fig. S2). Women with 0 
contacts were likely to live closer to facilities than those with 1–3 
contacts; these latter women had higher rates of fetal and neonatal 
mortality. Compared with women who received 1–3 contacts, other 
than maternal death and neonatal morbidity, all components of the 
primary outcome were significantly reduced with at least four contacts. 
Our study design and operational plan had several strengths. We 
successfully engaged civil society, from women themselves, their fa-
milies, faith leaders, and government ministries. Complementing the 
existing health care system by task-sharing, the LHWs used the POM 
mHealth platform to conduct independent antenatal and postnatal visits 
and collect their findings. Our community-based data collection pro-
cedures resulted in a low (< 5%) loss to follow-up despite enrolment of 
nearly 40,000 pregnancies. However, including only married women 
with settled addresses excluded single and internally displaced women 
at higher risk of adverse outcomes; the trial was conducted following 
the significant internal displacement related to the 2010 Indus River 
floods. 
Notwithstanding the careful design of the intervention, the effect 
could have been limited by a number of factors. There were insufficient 
LHWs to deliver the intervention to reach all sections of the population, 
as demonstrated by < 80% of women receiving a POM visit and < 80% 
compliance with the pre-specified schedule of visits when they oc-
curred. The LHWs have significant tasks related to participation in the 
periodic polio eradication campaigns which overall took almost a third 
of their time. The annual community engagement may not have been 
sufficient to induce awareness and behaviour change. We had based our 
threshold for treatment and referral due to systolic hypertension to 
increase generalisability where functioning sphygmomanometers and 
training are lacking; in retrospect, this may have limited the impact of 
the CLIP intervention as CLIP data have shown that non-severe hy-
pertension was predominately isolated diastolic hypertension [23]; the 
advent of low-cost, validated (in pregnancy and pre-eclampsia), semi- 
automated BP devices has mitigated some of the BP measurement 
concerns [18]. However, despite acceptance and ready application in 
training programmes, the lack of impact of three technological in-
novations (BP measurement device, POM and pulse oximetry) also 
raises the question of the role of technology in increasing community 
engagement and effectiveness of these frontline workers. The fact that 
there was no impact on knowledge and awareness of pre-eclampsia and 
danger signs among participating women suggests that these dom-
iciliary interactions by LHWs may not have been effective. Finally, 
despite recruiting almost 36,000 women (and almost 40,000 pregnan-
cies), we may have been underpowered to find a difference between 
trial arms as power is determined by cluster number and the between- 
cluster outcome rate variability was greater than anticipated (i.e., ICC 
0·044). 
We undertook community-ascertainment of outcomes. While mea-
sures of self-reported maternal, fetal, and neonatal outcomes have been 
validated in other studies [24], misreporting may have occurred. Also, 
the process of community engagement may have sensitised intervention 
cluster women and their families to disproportionately report adverse 
events which could explain the higher reported event rates in the in-
tervention clusters in the first surveillance quarter. We were unable to 
use physical examination or chart review to confirm diagnoses, by 
virtue of the personnel who provided care (i.e., LHWs) and the location 
of that care (i.e., in the community where there is no health record). 
However, to mitigate this, a group allocation-masked physician review 
to adjudicate every reported maternal, fetal or newborn death or major 
Fig. 2. Trial profile – Intervention vs. control allocation clusters.  
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morbidity, was performed. Recall bias risks were minimised by con-
ducting quarterly surveillance cycles. 
Our population-based estimates of maternal, fetal, and neonatal 
mortality tended to be higher than those previously published for 
Pakistan. Most previous estimates for Pakistan have been facility-based. 
Our maternal mortality estimate was 323/100,000 livebirths (com-
pared with 259 (AMANHI cohort of 31,114 pregnancies in Matiari) [25] 
and 299 (secondary analysis of the WHO Multicountry Survey 2011)  
[26]. For stillbirths, our estimate was 57·5/1000 livebirths (compared 
with 42·8 and 27·6/1000 livebirths for Matiari and nationally, respec-
tively).[2,25] Our estimate of neonatal mortality was 60·4/1000 live-
births (compared with 46·9 and 55/1000 livebirths for Matiari and 
nationally [Pakistan DHS 2011–12], respectively [27]. For stillbirths, 
these differences may have reflected more comprehensive and accurate 
ascertainment of outcomes that may have been previously misclassified 
as miscarriages in the community, and that may not have come to the 
attention of those providing facility-based care. 
The comparability of our community-ascertained rates of morbidity 
are more difficult to assess, as comparable published data are limited 
and facility-based. Our incidence of maternal sepsis (7·4%) was much 
higher than the recorded incidence of sepsis recorded in tertiary facil-
ities in Punjab and Sindh (1·3% in all women) [28]; however, this de-
finition of sepsis (comprising abortion-related infection, puerperal en-
dometritis, pyelonephritis, influenza-like illness, other systemic 
infections) excluded organ dysfunction whereas our broad definition of 
sepsis (fever and one of: abdominal/uterine tenderness, foul smelling 
vaginal discharge/lochia, productive cough and shortness of breath, 
dysuria or flank pain, headache and neck stiffness) could have captured 
associated complications related to organ dysfunction. The incidence of 
antepartum haemorrhage in our trial (3·2%) was within the range re-
ported in facility-based studies in Peshawar (3·0%) [29] or Hyderabad 
(5·4%). We found no comparable regional data on population level 
estimates of neonatal morbidities. 
A crucial factor limiting the effect on mortality and severe morbidity 
could also be the design which did not include facility-based inter-
ventions and care. Our hypothesis was that implementing community- 
level evidence-based care would reduce hypertension-related (and po-
tentially, all cause) maternal and perinatal mortality and major mor-
bidity, by addressing the ‘three delays’ in triage, transport, and treat-
ment. While we did undertake staff capacity enhancement throughout 
the district, we did not specifically put measures in place to improve 
quality of care. Poor-quality facility care and availability of key com-
modities could have limited the beneficial effect of community-level 
intervention on outcomes and negatively influenced community de-
mand; perceived poor quality of care at public hospitals is a significant 
barrier to seeking care [4], and health care providers in Sindh have 
gaps in their knowledge about the aetiology, diagnosis, and treatment 
of pre-eclampsia [6]. 
Finally, while the individual components of the complex CLIP in-
tervention were evidence-based, how these components interacted with 
one another and moderated any impact of the intervention remains 
unclear but will be the subject of pre-determined secondary analyses. 
The CLIP trial further confirms the ability of LHWs to task-share 
important aspects of maternity care, with favourable effects on 
Table 2 
Primary outcome.        
Intervention (n = 20,235 pregnancies) Control (n = 19,182 pregnancies) Adjusted OR* p-value  
Pregnancies with postpartum surveillance 18,419 17,335   
Infants 18,543 17,488   
Composite primary outcome† 5373 (26·6%) 4187 (21·8%) 1·20 [0·84–1·72] 0·31 
Maternal mortality 55 (0·3%) 51 (0·3%) 1·08 [0·69–1·71] 0·74 
Maternal morbidity 2196 (10·9%) 1707 (8·9%) 1·12 [0·57–2·16] 0·77 
(including maternal deaths)     
Obstetric sepsis 1477 (7.3%) 1191 (6·2%)   
Antepartum haemorrhage 643 (3.2%) 487 (2·5%)   
Blood transfusion 240 (1.2%) 168 (0.9%)   
Stroke 58 (0.3%) 79 (0·4%)   
Fistula 56 (0.3%) 39 (0·2%)   
Seizure 32 (0.2%) 18 (0·1%)   
Maternal coma 27 (0.1%) 25 (0·1%)   
Cardiopulmonary resuscitation 11 (0.1%) 17 (0·1%)   
Mechanical ventilation 11 (0·1%) 9 (0·0%)   
Disseminated intravascular coagulation 4 (0·0%) 8 (0·0%)   
Dialysis 2 (0·0%) 3 (0·0%)   
Interventions for major postpartum haemorrhage 2 (0·0%) 5 (0·0%)   
Perinatal mortality and late neonatal death 1942 (9·6%) 1906 (9·9%) 0·95 [0·86–1·03] 0·22 
Stillbirth 935 (4·6%) 951 (5·0%) 0·89 [0·81–0·99] 0·03 
Early neonatal death 819 (4·0%) 818 (4·3%) 0·95 [0·82–1·09] 0·46 
Late neonatal death 197 (1·0%) 150 (0·8%) 1·23 [0·97–1·55] 0·09 
Neonatal morbidity 2012 (11%) 1250 (7·2%) 1·22 [0·77–1·96] 0·40 
Neonatal morbidity (excluding deaths)     
Feeding difficulty 844 (4·2%) 385 (2.0%)   
Lethargy 585 (2.9%) 609 (3.2%)   
Hypothermia 405 (2.0%) 288 (1.5%)   
Jaundice 385 (1.9%) 389 (2.0%)   
Breathing difficulty 273 (1·3%) 223 (1.1%)   
Seizure 253 (1.3%) 261 (1.4%)   
Umbilical cord infection 284 (1·4%) 241 (1.3%)   
Coma 149 (0.7%) 109 (0.6%)   
Bleeding 82 (0·4%) 44 (0.2%)   
Central nervous system-related morbidity 12 (0·1%) 14 (0.1%)   
Skin infection 2 (0·0%) 1 (0·0%)   
Data presented as number (%) or number only. *Adjusted odds ratio presented as odds ratio [95% confidence interval]; adjusted for individual-level factors (maternal 
age, parity, maternal education, marital status, husband’s education, delivery location), and cluster-level factors (population density, baseline study neonatal 
mortality rate, healthcare worker density). † Defined as one/more of maternal morbidity or mortality, stillbirth, neonatal mortality, or neonatal morbidity. 
OR = odds ratio.  
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outcomes, as observed for newborns and children with other commu-
nity-level interventions in Pakistan [13,30]. For example, neonatal 
mortality was reduced by LHW-guided care (basic newborn resuscita-
tion and identification and treatment of suspected neonatal respiratory 
infections (RR 0·80 [0·68, 0·93]; p = 0·005)) [13] or LHW-led rural 
group sessions focussed on promotion of antenatal care and maternal 
health education, use of clean delivery kits, facility births, immediate 
newborn care, identification of danger signs, and promotion of care 
seeking (RR 0·85 [0·76, 0·96]; p = 0·02) [30]. Other community-level 
interventions in Pakistan have noted similar non-specific temporal 
improvements to those that we observed, and also highlighted the 
limitation of technology- and home-based care strategies for reducing 
newborn mortality when separated from facility enhancement [13]. 
5. Conclusions 
Pakistan is striving to meet global targets for the sustainable de-
velopment goals to improve maternal, fetal, and newborn outcomes 
while tackling the challenge of limited human resources, especially 
skilled medical professionals in its rural and remote populations. This 
was the genesis of our study to evaluate what could be done to mitigate 
the morbidity and mortality associated with pre-eclampsia. The CLIP 
Pakistan Trial demonstrates that an existing cadre of public sector 
community health workers can use technology to provide accurate and 
objective referral advice in pregnancy and engage and mobilize com-
munities. However, as implemented, the intervention did not improve 
outcomes. To achieve benefits on mortality and severe morbidity, these 
efforts must be complemented with facility-based strengthening of 
quality clinical care and facilitation of community-to-facility referral to 
achieve maximal impact on the unacceptably-high burden of death and 
morbidity in such settings. 
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